Clinical studies have also shown that KRAS mutations could be considered as a marker for the poor prognosis of pancreatic cancer.17 However, it has been reported that various KRAS mutations affect diverse signaling pathways, leading to distinct functional consequences. Here, KRAS is linked to familial pancreatic carcinoma.